In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B
- 1 January 1999
- journal article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 33 (1) , 7-11
- https://doi.org/10.1016/s0732-8893(98)00102-3
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- In Vitro Activity of Voriconazole Against Candida SpeciesDiagnostic Microbiology and Infectious Disease, 1998
- In Vitro Activities of Voriconazole (UK-109,496) and Four Other Antifungal Agents against 394 Clinical Isolates of Candida sppAntimicrobial Agents and Chemotherapy, 1998
- In vitro evaluation of voriconazole against some clinically important fungiAntimicrobial Agents and Chemotherapy, 1997
- In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogensAntimicrobial Agents and Chemotherapy, 1997
- Therapeutic Outcome in Invasive AspergillosisClinical Infectious Diseases, 1996
- A comparative study of the broth micro- and macro-dilution techniques for the determination of the in vitro susceptibility ofAspergillus fumigatusCanadian Journal of Microbiology, 1996
- In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida speciesAntimicrobial Agents and Chemotherapy, 1996
- Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungiAntimicrobial Agents and Chemotherapy, 1995
- NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosisThe American Journal of Medicine, 1994
- Aspergillosis and other systemic mycoses. The growing problemJAMA, 1979